度伐利尤单抗致免疫相关性肺炎1例  

One Case of Immune-Related Pneumonia Caused by Dulvalizumab

作　　者：张展昱 戴洪海 杨宁 孙晓琳[1,2] 许林宗[1,2] 李晓梅 

机构地区：[1]山东大学,山东 济南 [2]山东省立医院肿瘤治疗中心,山东 济南 [3]山东第一医科大学附属省立医院肿瘤治疗中心,山东 济南

出　　处：《临床医学进展》2022年第5期4451-4455,共5页Advances in Clinical Medicine

摘　　要：中枢神经系统中免疫细胞的存在为肿瘤患者进行免疫治疗带来希望。其中,部分免疫检查点抑制剂已应用于临床,程序性死亡配体-1的抑制剂通过激活免疫系统发挥抗肿瘤作用。近年来免疫治疗在肿瘤治疗中的地位越来越高,度伐利尤单抗也应用于小细胞肺癌治疗,但随之而来的免疫抑制剂导致的免疫相关性肺炎受到人们关注。本文为1例度伐利尤单抗致免疫相关性肺炎的相关病例报道。The presence of immune cells in the central nervous system holds promise for immunotherapy of small-cell lung cancer. Some of these immune checkpoint inhibitors are already in clinical use, and inhibitors of programmed cell death-Ligand 1 exert anti-tumor effects by activating the immune system. In recent years, immunotherapy has become more and more important in tumor treatment, and dulvalizumab is also used in the treatment of small cell lung cancer, but the consequent immunosuppression-induced immune-associated pneumonia has received attention. In this paper, we present a case report related to immune-associated pneumonia caused by dulvalizumab.

关 键 词：免疫疗法 度伐利尤单抗 肺炎 药物不良反应 

分 类 号：R563.1[医药卫生—呼吸系统]